Full text

Turn on search term navigation

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The extract of Paspalum thunbergii, a native perennial herb in Korea belonging to the rice family, was investigated for its anti-inflammatory activity and the underlying mechanisms driving its effects. Fifteen chemical components of the P. thunbergii extract, including rosmarinic acid and isoquercitrin, were identified using LC-MS. The extract showed antioxidative activity through DPPH and ABTS cation radical scavenging activity. The P. thunbergii extract significantly inhibited lipopolysaccharide (LPS)-induced nitric oxide (NO) production in macrophage RAW 264.7 cells. The extract inhibited the expression of lipopolysaccharide-induced iNOS and COX-2, which are inflammation-related enzymes. To explore the underlying anti-inflammatory mechanism, the expression levels of signal proteins related to MAPK, NF-κB, JAK/STAT, and Wnt/β-catenin signaling were measured. As a result, the P. thunbergii extract inhibited the expression of p-p38, and p-JNK increased by LPS in RAW 264.7 cells. Additionally, it decreased the expression of LPS-induced p-IKKβ and p-NF-κB p65 and prevented the migration of p-NF-κB into the nucleus caused by LPS. Notably, p-JAK1, p-STAT3, Wnt 3α, β-catenin, and p-GSK-3β protein expressions were also inhibited. Therefore, the prominent anti-inflammatory activity of the P. thunbergii extract may be via the MAPK, NF-κB, JAK/STAT, Wnt/β-catenin signal pathway.

Details

Title
Lipopolysaccharide-Induced Inflammatory Response and Its Prominent Suppression by Paspalum thunbergii Extract
Author
Ha, Bin 1 ; Ji-Hye Kang 2   VIAFID ORCID Logo  ; Kim, Do Hyun 3 ; Mi-Young, Lee 4   VIAFID ORCID Logo 

 Department of Medical Science, College of Medical Science, Soonchunhyang University, Asan-si 31538, Chungcheongnam-do, Republic of Korea; [email protected] 
 Department of Medical Biotechnology, College of Medical Science, Soonchunhyang University, Asan-si 31538, Chungcheongnam-do, Republic of Korea; [email protected] 
 Department of Research and Development, Eshel Biopharm Co., Ltd., Asan-si 31538, Chungcheongnam-do, Republic of Korea; [email protected] 
 Department of Medical Science, College of Medical Science, Soonchunhyang University, Asan-si 31538, Chungcheongnam-do, Republic of Korea; [email protected]; Department of Medical Biotechnology, College of Medical Science, Soonchunhyang University, Asan-si 31538, Chungcheongnam-do, Republic of Korea; [email protected]; Department of Research and Development, Eshel Biopharm Co., Ltd., Asan-si 31538, Chungcheongnam-do, Republic of Korea; [email protected] 
First page
1611
Publication year
2025
Publication date
2025
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3171027082
Copyright
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.